Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for European expansion.

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...

Trump's tariffs could derail Europe's 2025 growth, say top Wall Street analysts. Goldman Sachs sees eurozone GDP at 0.7%, ...

The global vulvodynia treatment market is poised for significant growth, with sales expected to rise from USD 6.7 billion in 2025 to USD 12.4 billion by 2035, reflecting a CAGR of 6.3% over the ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...